Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

被引：154

作者：

Chia, Puey Ling ^{[1
]}

Mitchell, Paul ^{[1
]}

Dobrovic, Alexander ^{[2
,3
,4
]}

John, Thomas ^{[1
,2
,4
]}

机构：

[1] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Heidelberg, Vic, Australia

[2] Austin Hlth, Ludwig Inst Canc Res, Melbourne, Vic, Australia

[3] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia

[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic 3086, Australia

来源：

CLINICAL EPIDEMIOLOGY | 2014年 / 6卷

关键词：

anaplastic lymphoma kinase (ALK); gene rearrangements; lung cancer; kinase inhibitors; lung adenocarcinoma; ANAPLASTIC LYMPHOMA KINASE; POLYMERASE CHAIN-REACTION; EML4-ALK FUSION VARIANTS; ACQUIRED-RESISTANCE; NEVER-SMOKERS; MOLECULAR CHARACTERIZATION; BRAF GENE; EGFR; MUTATIONS; IMMUNOHISTOCHEMISTRY;

D O I：

10.2147/CLEP.S69718

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.

引用

页码：423 / 432

页数：10

共 102 条

[1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].

Aberle, Denise R. ;

Adams, Amanda M. ;

Berg, Christine D. ;

Black, William C. ;

Clapp, Jonathan D. ;

Fagerstrom, Richard M. ;

Gareen, Ilana F. ;

Gatsonis, Constantine ;

Marcus, Pamela M. ;

Sicks, JoRean D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409

[2]

Altavilla G, 2010, ASCO P S, V28, p565S

[3]

[Anonymous], J CLIN ONCOL S1

[4]

[Anonymous], 2012, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

[5]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[6] Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer [J].

Bardelli, Alberto ;

Corso, Simona ;

Bertotti, Andrea ;

Hobor, Sebastijan ;

Valtorta, Emanuele ;

Siravegna, Giulia ;

Sartore-Bianchi, Andrea ;

Scala, Elisa ;

Cassingena, Andrea ;

Zecchin, Davide ;

Apicella, Maria ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Lauricella, Calogero ;

Zanon, Carlo ;

Perera, Timothy ;

Veronese, Silvio ;

Corti, Giorgio ;

Amatu, Alessio ;

Gambacorta, Marcello ;

Diaz, Luis A., Jr. ;

Sausen, Mark ;

Velculescu, Victor E. ;

Comoglio, Paolo ;

Trusolino, Livio ;

Di Nicolantonio, Federica ;

Giordano, Silvia ;

Siena, Salvatore .

CANCER DISCOVERY, 2013, 3 (06) :658-673

[7] Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function [J].

Basso, AD ;

Solit, DB ;

Chiosis, G ;

Giri, B ;

Tsichlis, P ;

Rosen, N .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39858-39866

[8] Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor [J].

Bridge, JA ;

Kanamori, M ;

Ma, ZG ;

Pickering, D ;

Hill, DA ;

Lydiatt, W ;

Lui, MY ;

Colleoni, GWB ;

Antonescu, CR ;

Ladanyi, M ;

Morris, SW .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :411-415

[9] Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances [J].

Cabillic, Florian ;

Gros, Audrey ;

Dugay, Frederic ;

Begueret, Hugues ;

Mesturoux, Laura ;

Chiforeanu, Dan Cristian ;

Dufrenot, Leila ;

Jauffret, Vincent ;

Dachary, Dominique ;

Corre, Romain ;

Lespagnol, Alexandra ;

Soler, Gwendoline ;

Dagher, Julien ;

Catros, Veronique ;

Le Calve, Michele ;

Merlio, Jean-Philippe ;

Belaud-Rotureau, Marc-Antoine .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) :295-306

[10] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

← 1 2 3 4 5 6 7 8 9 10 →